Millennium Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Millennium Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-37,018	Closed	-$85.9K	–	6582
2024 Q2	$85.9K	Sell	37,018 -561	-1%	-$1.45K	﹤0.01%	5337
2024 Q1	$106K	Buy	+37,579	New	+$111K	﹤0.01%	5561
2023 Q3	–	Sell	-14,940	Closed	-$49.3K	–	6680
2023 Q2	$49.3K	Sell	14,940 -19,402	-56%	-$68.5K	﹤0.01%	5478
2023 Q1	$116K	Buy	34,342 +14,305	+71%	+$50.1K	﹤0.01%	5373
2022 Q4	$72K	Buy	+20,037	New	+$131K	﹤0.01%	5685
2021 Q4	–	Sell	-15,348	Closed	-$146K	–	7501
2021 Q3	$146K	Buy	+15,348	New	+$144K	﹤0.01%	6259
2020 Q2	–	Sell	-37,760	Closed	-$321K	–	4694
2020 Q1	$321K	Sell	37,760 -7,119	-16%	-$99.5K	﹤0.01%	3141
2019 Q4	$1.02M	Sell	44,879 -10,882	-20%	-$155K	﹤0.01%	2994
2019 Q3	$797K	Sell	55,761 -21,380	-28%	-$314K	﹤0.01%	2980
2019 Q2	$1.03M	Buy	77,141 +74,857	+3,277%	+$1.13M	﹤0.01%	2801
2019 Q1	$40K	Buy	2,284 +1,057	+86%	+$15.8K	﹤0.01%	3906
2018 Q4	$17K	Buy	+1,227	New	+$21.6K	﹤0.01%	3675
2018 Q3	–	Sell	-14,617	Closed	-$626K	–	4353
2018 Q2	$626K	Sell	14,617 -7,750	-35%	-$355K	﹤0.01%	3064
2018 Q1	$1.46M	Sell	22,367 -238,451	-91%	-$16.9M	﹤0.01%	2500
2017 Q4	$19M	Buy	260,818 +116,528	+81%	+$9.64M	0.03%	926
2017 Q3	$13.2M	Buy	144,290 +118,243	+454%	+$9.07M	0.02%	1052
2017 Q2	$1.72M	Buy	26,047 +15,571	+149%	+$1.93M	﹤0.01%	2159
2017 Q1	$2.27M	Sell	10,476 -48,860	-82%	-$6.98M	﹤0.01%	1934
2016 Q4	$5.49M	Buy	59,336 +18,034	+44%	+$2.03M	0.01%	1271
2016 Q3	$5.58M	Sell	41,302 -5,219	-11%	-$518K	0.01%	1272
2016 Q2	$4.71M	Buy	46,521 +15,018	+48%	+$1.86M	0.01%	1297
2016 Q1	$5.16M	Buy	31,503 +3,528	+13%	+$715K	0.01%	1238
2015 Q4	$9.16M	Buy	27,975 +25,989	+1,309%	+$8.46M	0.02%	970
2015 Q3	$641K	Sell	1,986 -28,637	-94%	-$12.6M	﹤0.01%	2530
2015 Q2	$12.2M	Buy	30,623 +27,574	+904%	+$11.7M	0.02%	860
2015 Q1	$1.5M	Buy	+3,049	New	+$1.18M	﹤0.01%	2117
2014 Q4	–	Sell	-3,422	Closed	-$660K	–	4340
2014 Q3	$660K	Sell	3,422 -2,758	-45%	-$606K	﹤0.01%	2571
2014 Q2	$1.48M	Buy	+6,180	New	+$1.26M	﹤0.01%	1967
2014 Q1	–	Sell	-61,301	Closed	-$12.1M	–	3965
2013 Q4	$12.1M	Buy	61,301 +17,813	+41%	+$3.17M	0.04%	586
2013 Q3	$7.35M	Buy	43,488 +33,283	+326%	+$5.36M	0.02%	892
2013 Q2	$1.81M	Buy	+10,205	New	+$1.45M	0.01%	1644

Other funds holding LUMO

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

GWM

Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Millennium Management's LUMO Position: Q3 2024 in Review

Millennium Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2024, closing a stake of 37,018 shares — an estimated $85.9K sold.

Millennium Management first reported a position in LUMO in Q2 2013 and held it in 31 quarters. The position peaked at $19M in Q4 2017. 28 funds tracked by Wall St. Rank hold LUMO as of Q3 2024.

Millennium Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Millennium Management sold 37,018 Lumos Pharma, Inc. Common Stock shares in Q3 2024, an estimated $85.9K.
Millennium Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 31 quarters.
Millennium Management's Lumos Pharma, Inc. Common Stock position peaked at $19M in Q4 2017.
28 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2024.

Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.